Investor Information

Announcements & Press Releases

Nit Enterprises, INC. Completes High Altitude Aircraft Radiation Testing Experiment November 1, 2016

Palm Beach Gardens, Florida –  November 1, 2016 –

NIT Enterprises, Inc. (NITE) a dynamic technology Company developing lightweight, radiation absorbing, patented, nucleotide materials for industrial use to protect against the harmful effects of X-Rays, Gamma Rays, and high energy Ultraviolet radiation.

 

During May, 2015, the Company conducted a test to calculate the radiation dosage as a function of altitude and proximity to the north polar circle. Results are expected to yield a definitive model reflecting the high level of radiation absorbed by aircraft, pilots and passengers while traveling at high altitudes (~40,000 feet) near and around the earth’s polar circles.

 

The test was flow in a Boeing 777 Aircraft on a flight from the East Coast to Shanghai on a commercial passenger flight.  At the request of the airline, the pilots name and the carriers name will be kept confidential as the subject is controversial.

 

The instrumentation for the flight used a recording Geiger Counter which was programmed and supplied for the event by Michael C. Latimer, Associate Professor at Palm Beach State College in Palm Beach Gardens, FL. Mr. Latimer has been elected to serve as the 2015-16 president-elect of the board of directors of the American Society of Radiologic Technologists. After one term as president-elect, he will serve one term as president and one term as chairman of the board.

 

Mr. Latimer will be writing a third party report on the data he extracts from the Geiger Counter instrumentation. The data is expected to bring new light to the subject of high altitude flight.

 

The risks to aircrew and passenger health posed by prolonged exposure to low levels of ionizing radiation at aircraft altitudes have recently received renewed attention. Civil and military aircraft currently on the drawing board are expected to operate at higher altitudes and fly longer ranges than do existing aircraft, thereby exposing their flight crews and passengers to higher levels of ionizing radiation, for longer periods of time.

 

Future plans include entering into the aircraft and space radiation protection market for the protection of both people and electronics, where weight is critical.

 

The ability to shield medical and industrial materials without using heavy metals allows NITE’s technology to be applied in a myriad of applications where shielding is not possible for reasons of weight and size of currently existing methods. Application of NITE’s shielding technologies provides a unique tool for new and existing product enhancements in healthcare, defense, space and industrial environments.

 

Gary R. Smith, CEO, of NITE stated “This experiment is the second in a series of in-house testing being designed for demonstration and presentation to the United States Military, Department of Homeland Security and for other industrial/commercial security purposes “.

 

The Company plans to enter the public market by filing Form S-1 (IPO)

 

About NIT Enterprises, Inc. (NITE)  (http://www.nitenterprise.com/)

NIT Enterprises, Inc. (d/b/a Nucleotide Industrial Technologies) (NITE) was created to improve public safety and to provide a new measure of protection for commercial, industrial, and personal products that enhance the longevity of living and non-living substances based upon unique proprietary NA technologies developed by our award winning scientist and technology team. This new technology is the infusion of ingredients, known as nucleotides, into a multiplicity of common products enhanced by their presence. The Nucleotides were derived by atomic level research that demonstrates their ability to provide Ultraviolet (UV) rays screening capability at the molecular level.

 

Cautionary Statement Concerning forward-Looking Statements:

 

This press release contains forward-looking statements that can be identified by words such as “anticipates,””intends,””plans,””seeks,””believes,””estimates,””expects” and similar references to future periods.

 

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

 

Corporate Contact Information: NIT Enterprises Inc. Harbour Financial Center, 2401 PGA Boulevard, Suite 272, Palm Beach Gardens, FL 33410; Phone: 561-508-6941

 

Investor Relations:  Corporate Secretary; Email: NITEnterprises@yahoo.com

NIT Enterprises, INC. To Enter Joint Venture With Major Plastics Manufacture 3/20/2016

Palm Beach Gardens, Florida – March 20, 2016 –

 

NIT Enterprises, Inc. (NITE) is a unique and dynamic technology Company developing patented lightweight nucleotide based materials used to negate the harmful effects of X-Rays, Gamma Rays, and high energy Ultraviolet radiation.

 

The Company is in discussions to enter into a Joint Venture with one of the largest worldwide plastics technology companies to develop lightweight flexible curtains, protection vests, and solid plastic radiation absorbers for medical and patient protection.

 

The company’s initial market thrust will be license its technology into the medical market for doctor, nurse, and patient protection from radiation sources in hospitals and medical facilities.  The company’s technology uses a lightweight genetic mechanism to absorb radiation that does not require heavy metallic compounds.

 

Future plans include entering into the aircraft and space radiation protection market for the protection of both people and electronics, where weight is critical.

 

The ability to shield medical and industrial materials without using heavy metals allows NITE’s technology to be applied in a myriad of applications where shielding is not possible for reasons of weight and size of currently existing methods. Application of NITE’s shielding technologies provides a unique tool for new and existing product enhancements in healthcare, defense, space and industrial environments.

 

Gary Smith, CEO, of NITE stated “This joint venture opportunity will become NITE’s initial baseline revenue source. The potential revenues to be generated by commercialization of these exclusive technologies can be exploited through manufacturing and licensing production for disruptive applications which are also expected to generate significantly more intellectual property enhancements”.

 

The Company plans to enter the public market, filing Form S-1 (IPO)

 

About NIT Enterprises, Inc. (NITE)  (http://www.nitenterprises.com/)

NIT Enterprises, Inc. (d/b/a Nucleotide Industrial Technologies) (NITE) was created to improve public safety and to provide a new measure of protection for commercial, industrial, and personal products that enhance the longevity of living and non-living substances based upon unique proprietary NA technologies developed by our award winning scientist and technology team. This new technology is the infusion of ingredients, known as nucleotides, into a multiplicity of common products enhanced by their presence. The Nucleotides were derived by atomic level research that demonstrates their ability to provide Ultraviolet (UV) rays screening capability at the molecular level.

 

Cautionary Statement Concerning forward-Looking Statements:

 

This press release contains forward-looking statements that can be identified by words such as “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects” and similar references to future periods.

 

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

 

Corporate Contact Information: NIT Enterprises Inc. Harbour Financial Center, 2401 PGA Boulevard, Suite 272, Palm Beach Gardens, FL 33410; Phone: 561-508-6941

 

Investor Relations: Email: NITEnterprises@yahoo.com

NIT ENTERPRISES, INC. ANNOUNCES A LETTER OF INTENT TO PERFORM A JOINT DESIGN OF A LIGHTWEIGHT MEDICAL X-RAY VEST WITH PROTECH MEDICAL INC. 1/24/2017

Palm Beach Gardens, Florida – 1/24/2017

In the last quarter of 2016 NIT Enterprises, Inc. (“NIT”) achieved attenuation of X-Rays using processed lightweight genetic material meeting the government recommended specification, NCRP-#102; providing the required equivalent shielding thickness of .5 mm of lead.  During this period, NIT scientists also achieved a 99% protection from Gamma Rays using its Cesium-137 source in its laboratory lead chamber measurements.  This level of Gamma protection was achieved with just a few grams of non-toxic formulation of a genetic material processed with a heavy metal and a rare earth.

As a result of NIT’s technical success, NIT signed a Letter of Intent with Protech Medical, Inc. (a DBA of parent company Protech Leaded Eyewear, Inc.) also of Palm Beach Gardens, Florida, for joint work to design a production medical X-Ray vest that would weigh approximately 80% less than current leaded vests.

The weight of medical vests is very cumbersome to doctors and medical personnel who perform lengthy operations using X-Ray fluoroscopes.  Many orthopedic and neurological doctors often have to perform 3 to 8-hour surgeries, wherein the the vest weight causes them to overheat and suffer exhaustion.  Protech Medical, a manufacturer and distributor of radiation protection equipment, states weight as the primary criteria medical personnel use in choosing protection equipment.  Protech estimates a lightweight vest can be sold for a significantly increased price and every current manufacturer will wish to switch over to the NIT genetic media in their product offerings.

As such, the Letter of Intent envisions Protech, which currently manufactures lighter weight media, to be the absorption material manufacturer of the NIT technology, under license, and distribute the material to all other vest manufacturers worldwide.

Gary R. Smith, CEO of NIT, states the relationship with Protech is gaining the attention of manufacturers of other radiation protection technology in electronics, the miltary, the nuclear industry, and homeland security applications.  Smith further projects more patent filings as NIT continues to develop more applications for the technology.

NIT is a research and devleopment company and intends to license its technologies to specific radiation protection markets to gain revenue growth.